About Conference

ConferenceSeries Ltd warmly welcomes all the delegates around the world to participate in the International conference on Chest which is to be held on November 17-18, 2016 at Dubai, UAE. This meeting deals with the current research developments in the field of pulmonology, Cardiology and also about the new treatment methods which are devised by scientists to treat various diseases in easier way.  This meeting acts as a best platform for attendees to learn about the recent trends in pulmonary research and development. This conference also includes keynote lectures, interactive sessions, plenary talks, speech from young researchers, workshops and also poster presentations from students on the topic Chest 2016. This event will be a constructive event for all the attendees providing a snap shot of the types of on-going research work in Pulmonology and Cardiology

The main theme of the conference is “Comprehensive approach towards Cardiology and pulmonology research”.  This would be a two day conference which triggers the innovative minds of the attendees. The topics of the  conference is cardiac diseases, diagnosis of lung and cardiac diseases, stroke, chest imaging, Cardiothoracic surgery, Lung and metabolism, Lung Infections, Lung Disorders, Pulmonary Disease, Tuberculosis, Pneumonia, Lung Cancer and Treatment Strategies, respiratory tract and associated defense mechanism, biological and pathological effects, Advanced Diagnostic Techniques for Prevention, Control Management and cure  for Lung Disorders, Novel and Futuristic Research Aspects and Clinical Trials. Poster presentation enables them to present their research work in form of posters and also e-posters with live streaming.

Market Analysis Report

Pulmonary medicine is poised to replace cardiology as the significant new opportunity for medical device manufacturers as options for diagnosing, monitoring and treating the substantial patient populations with chronic obstructive pulmonary disease, asthma, lung cancer and other pulmonary conditions transform from clinical trials to commercialization and adoption. These emerging technologies will increase their share of the pulmonary technologies market from 10% in 2009 to 56% in 2015, with gains concentrated in therapeutics based largely on advances in interventional bronchoscopy. New approaches to standard therapies, such as high flow nasal oxygen delivery, will also contribute, as well new technologies designed to enhance the accuracy of pulmonary diagnostics while reducing their invasiveness.

The global AF surgery product market was worth $791.5 Million in 2014 and is estimated to reach $1.73 Billion by 2020. The interventional cardiology and peripheral vascular devices market is expected to reach $26.72 Billion by 2019 from $18.73 Billion in 2014. The global respiratory care devices market was expected to be worth $8.8 billion in 2010 and is estimated to reach $13.5 billion by 2015, growing at a CAGR of 8.8% from 2010-2015. Transparency Market Research (TMR) has announced the release of a new research report based on the global oxygen therapy devices market that estimates the overall value of the market to be US$2.80 billion by 2020, expanding at a CAGR of 5.7% during the period from 2014 to 2020.

Global pulmonary drug delivery systems market is expected to witness lucrative market growth over the forecast period including increasing incidences of chronic diseases such as tuberculosis and diabetes mellitus.

Why to attend?

                        International Conference on Chest to bring together worldwide distinguished academics in the field of Cardiologists, Pulmonologists, Pulmonary specialists, Respiratory specialist , Chest medicine specialist, Respirologists,  Public Health professionals, Scientists, Academic scientists, Industry researchers, Scholars to exchange about state of the art Research and Technologies and to bring discoveries of cancer to Patients. To understand the current state of research and the challenges to future discovery. Attending International conference is for the Professional Development.

                        The aim of the Conference is to provide a platform to academicians and practitioners from multiple disciplines to debate and deliberate on social change that is encompassed by innovation and technology.

Target Audience:

• Directors/CEO & Research Scientists 
• Neurologists and  Neurosurgeons
• Neuropsychiatrists, Therapists & Pediatricians
•  
• Respiratory Faculty and Students
• Heart, Lung and Respiratory Associations and Societies
• Business Entrepreneurs
• Thoracic surgeons, Radiologists
• Medical and Nursing Students, Professors
• Pharmaceutical companies
• Manufacturing Medical Devices Companies

Track 1: Cardiovascular Diseases

Cardiology is the division of medicine concerned with the illness of heart and the blood vessels, which also involves diagnosis and treatment of the diseases. Heart diseases are said to be cardiovascular Disease which is a major cause of disability and premature death throughout the world. Acute coronary events (heart attacks) and cerebrovascular events (strokes) occur suddenly, and are often fatal before medical care can be given. Symptoms include shortness of breath, chest pain, and extreme fatigue. Cardiology conferences promote awareness against risk factor modification about the heart diseases. It reduces clinical events and premature death in people with cardiovascular disease risk. Cardiovascular disease is treatable with initial treatment primarily focused on diet and lifestyle interventions.

Track 2: Stroke

Stroke is the sudden brain attack. It happens when the blood flow to the brain is blocked or rupturing of blood vessels. Ischemic stroke occurs when an artery to the brain is blocked.  The brain depends on its arteries to bring fresh blood from the heart and lungs. The blood carries oxygen and nutrients to the brain, and takes away carbon dioxide and cellular waste. If an artery is blocked, the brain cells cannot make enough energy and will eventually stop working. If the artery remains blocked for more than a minute, the apoptosis of brain cells will occur and also structural integrity of brain tissue and blood vessel will be lost. The most common problem is narrowing of the arteries in the neck or head. This is most often caused by atherosclerosis, or gradual cholesterol deposition. It is mostly observed in women and children.

Track 3: Arrhythmia

Cardiac arrhythmia means irregular heart beat or heart rhythm where muscles of heart contract in a coordinated fashion to insure that blood is been efficiently pumped into the arteries and the extra heart beat are due to premature atrial contraction and premature ventricular contraction. The electrical impulses are responsible for arrhythmia condition. The Wolff–Parkinson–White syndrome (WPW) is one of the disorders of electrical system of the heart which are commonly referred to as pre-excitation syndromes which is caused by the presence of an abnormal accessory electrical conduction pathways between the atria and ventricles. Treatments may include physical maneuvers, medications, electrical conversion, electro-or cryo-cautery. Arrhythmia can be managed from various ways such as SCA risk assessments, non-invasive techniques, clinical electrophysiology are some clinical techniques and epidemiology of cardiac arrhythmia. 

Track 4: Peripheral artery diseases

Peripheral artery disease (PAD) is a narrowing of the peripheral arteries in legs, stomach, arms, and head by forming plaque inside the arteries. Mostly the arteries of legs get affected. The blocked blood flow to the legs can cause pain and numbness. It can also raise risk of getting an infection resulting in tissue death (gangrene).  PAD increases your risk of coronary heart disease, heart attack, stroke, and transient ischemic attack. PAD can be treated by lifestyle changes, medicines and revascularization.

Track 5: Congenital heart diseases

Congenital heart defects are problems with the heart's structure that are present at birth. Congenital heart defects change the normal flow of blood through the heart. This defect develops in the womb, before the baby is born. During pregnancy the mother having some infections such as rubella or poorly controlled type 1 or type 2 diabetes can cause CHD. Some genetic disorders such as Down syndrome or any chromosome defects leads to CHD. Congenital heart disease affects 8 out of every 1,000 newborns. Each year, more than 35,000 babies in the United States are born with congenital heart defects

Track 6: Cardiac surgery

Cardiac surgery is the field of medicine involved in surgical treatment of diseases affecting organs inside the thorax generally treatment of conditions of the heart and lungs by the cardiac surgeons. Coronary artery bypass grafting (CABG) is done to restore normal blood flow to heart muscle. Cardiac cognitive impairment, Cardiac valve disease, Atrial sepal defect repair, Ventricular sepal defect repair are done for cardiac surgery. Pediatric heart surgeons treat complex congenital heart defects in newborns, children, and adolescents. During open heart surgery the heart-lung bypass machine takes over the function of the heart and lungs to provide oxygenated blood to the body. Post-surgical procedure helps the patients to heal the surgical wound and also from infections.

Track 7: Pulmonary disorder

Pulmonary disease is a term that encompasses pathological conditions affecting the organs and tissues of the lungs and the respiratory tract. It includes the upper respiratory tract, trachea, bronchi, bronchioles, alveoli, pleura and pleural cavity. The lung disease may cause inflammation, restrictive or infections to the respective tissues. Major cause of pulmonary disease is due to smoking, occupational exposures and also the genetic makeup of an individual. Pulmonary diseases may also impact newborns, such as pulmonary hyperplasia and Infant respiratory distress syndrome.

Track 8: Chronic obstructive pulmonary disease

Chronic obstructive pulmonary disease (COPD) is a progressive lung disease that makes it hard to breathe. It develops slowly. Symptoms often worsen over time and can limit your ability to do routine activities. Severe COPD may prevent you from doing even basic activities like walking, cooking etc. Alpha1-antitrypsin deficiency (AATD) is a relatively common genetic condition for Chronic obstructive pulmonary disease.  People with AATD are predisposed to obstructive pulmonary disease and liver disease.  Adult stem cell therapy is a new alternative treatment to help manage the complications of COPD. This stem cell heal the plagued cell with disease

Track 9: Lung Cancer

Lung cancer is results of unconditional cell growth in tissues of the lungs by the process of metastasis. Large numbers of people are suffering from lung carcinoma due to long time smoking and also second-hand smoke. The abnormal activation of genes in normal cell leads to carcinoma.  Molecular oncology involve in finding out genes that are responsible for the development of cancer. Cancer cells differ from normal cells in size, structure, function, and growth rate. In cancer cells growth rate is faster. Common treatments include palliative care, surgery, chemotherapy, and radiation therapy. Bevacizumab is an anti- angiogenic monoclonal antibody in trials for advanced non- small cell lung cancer treatment.

Track 10: Pulmonary Hypertension

Pulmonary hypertension (PH) is the increase of blood pressure in the pulmonary artery, vein, or capillaries due to the narrowing of arteries and capillaries to and within the lungs, which leads to shortness of breath, dizziness, fainting, leg swelling and other symptoms. Symptoms of pulmonary hypertension do not usually occur until the condition has progressed. The first symptom of pulmonary hypertension is usually shortness of breath with everyday activities, such as climbing stairs. Fatigue, dizziness, and fainting spells also can be symptoms. The molecular mechanism of pulmonary arterial hypertension (PAH) is not known clearly. The endothelial dysfunction decreases the synthesis of endothelium-derived vasodilators such as nitric oxide and prostacyclin. Diagnosis of the severe heart condition includes mainly Echocardiography or as per the signs and symptoms of the particular disease condition. Treatment for pulmonary hypertension will not cure the condition but improve the quality of life.     

Track 11: Diagnosis of pulmonary disorder

Diagnosis is the act or process of identifying the nature and cause of a disease or injury through the systematic analysis of patient signs and symptoms. The physicians will do the physical examination of the patients followed by laboratory test such as Chest x-ray, pulmonary function tests, arterial blood gases, lung scan, Electrocardiogram (ECG), spirometry and Bronchoscopy. Angiography is an x-ray based technique used to image the veins, arteries, blood vessel. It is a part of projection radiography. The angiography devices market is expected to reach $27.7 billion by the year 2019

Track 12: Chest Imaging

Chest Imaging interprets cross sectional imaging studies of the heart and pulmonary system using Computed Tomography (CT or "CAT" scans) and Magnetic Resonance Imaging (MRI) with a volume of more than 2,500 studies each year. CT and MRI are non-invasive imaging modalities, meaning that no catheterization is required. MUSC operates the most up-to-date, cutting edge imaging equipment to ensure optimal diagnostic quality in patient care while also minimizing patient exposure to ionizing radiation. The chest radiograph imaging has some limitations in their use.

Track 13: Echocardiography

Echocardiography is a painless test that uses sound waves to create moving pictures of your heart. The pictures show the size and shape of your heart. They also show how well your heart's chambers and valves are working. It pin point areas of heart muscle that aren't contracting well because of poor blood flow or injury from a previous heart attack. It also detects possible blood clots inside the heart, fluid buildup in the pericardium and problems with the aorta. The American Society of Echocardiography (ASE) is a professional organization made up of physicians, sonographers, nurses, and scientists involved in the field of echocardiography. Echocardiography is performed by cardiac sonographers, cardiac physiologists (UK) or trained doctors in echocardiography. Echocardiography was invented by Milton R. Hejtmancik, MD, from which he was awarded the AMA Billings Gold Medal in 1972.

Track 14: Cardiovascular pharmacology

Cardiovascular pharmacology deals with the medication of cardiac diseases. The Cardiac Drugs are used to treat conditions of the heart or the circulatory or vascular system. Many classes of cardiovascular agents are available to treat the various cardiovascular conditions. In this sub topic we have Sodium, potassium, calcium channel blockers, ACE-inhibitors and Cardiac biomarkers. There are 6 associations and societies and the main association for Cardiac Therapeutic Agents in USA. 50 universities are working on Cardiac Therapeutic Agents. Three new drugs were introduced in 2015. There are many types of cardiovascular drugs in the market that include Cardiac glycosides, anti-coagulants, anti-arrhythmic agents, anti-anginal agents and anti-hypertensive agents.

Track 15: Pulmonary Therapy

Pulmonary therapy includes the program of exercise and treatment to help patients maintain and lung function. The treatments to help lung diseases are postural drainage, suctioning, and breathing exercises. It is defined by the American Thoracic Society and the European Respiratory Society. Pulmonary therapists are specialists and educators in pulmonology. They are often in charge of initiating and managing life support for people in intensive care units and emergency departments. The NICE clinical guideline on chronic obstructive pulmonary disease states that “pulmonary rehabilitation should be offered to every patient who considers themselves functionally disabled by COPD. Medications are Anti-inflammatory agents (inhaled steroids), Bronchodilators, Long-acting bronchodilators, Beta-2 agonists, Anticholinergic agents, Oral steroids, Antibiotics, Mucolytic agents, Oxygen therapy, or Preventative therapy.

Track 16: Heart and lung transplant

A heart transplant or a cardiac transplant is a surgical transplant procedure performed on patients with end-stage heart failure or severe coronary artery disease. Pediatric heart transplantation is important treatment choice in the end stage of heart disease in children. In heart transplantation some post-operative complications are there, those are infections, organ rejection as well as side effects due to immunosuppressive medications. There are selective criteria for potential lung donors due to the needs of the potential recipients, after lung transplantation several pulmonary infection occur especially viral infection by cytomegalovirus and rejection of organ. Cardiothoracic surgery is the field of medicine involved in surgical treatment of organs inside the thorax (the chest). Better supervision of medical complications leads to better long term outcomes.

Track 17: Implantable cardiac devices

The cardiac devices which are implant inside the body will monitor and control the heart rhythms. This devices are programmed to detect abnormal heart rhythms and deliver therapy via programmable anti-tachycardia pacing in addition to low-energy and high-energy shocks. Risk of ICD is that sometimes it leads to infection in the surgical site and failure to deliver therapy when it is needed. The global market for cardiac equipment grew from $49.4 billion in 2013 to $52 billion in 2014.

Track 18: Case reports on cardiac and pulmonary diseases

CVDs are the number 1 cause of death globally. More people die annually from CVDs than from any other cause. In 2012, 17.5 million people died due cardiac vascular disease. More than 3 million died due to COPD’s. 235 million people suffer from asthma, which is common among the children. Cardiac vascular disease and pulmonary disease are very invasive among developing countries than the developed countries. The aim of the WHO Chronic Respiratory Diseases Programme is to support Member States in their efforts to reduce the toll of morbidity, disability and premature mortality related to chronic respiratory diseases, and specifically, asthma and chronic obstructive pulmonary disease.

International Conference on Neuroimmunology and Neurological disorders

It is our pleasure to invite you to Neurology conference entitled International Conference on Neuroimmunology and Neurological Disorders which is held on September 26-27, 2018 in Montreal, Canada.

Sessions/Tracks

ConferenceSeries Ltd cordially invites all the participants from all over the world to attend International Conference on Chest 2016 during November 17-18, 2016 Dubai, UAE which includes prompt keynote presentations, Oral talks, Poster Presentations, Young Research Forum and Workshop.

Chest Conference aims at gathering the audience from all the major parts of the World with a goal to enhance the scientific knowledge by exploring the latest advancements in the related conference field area. The conference will include explicit keynote and plenary sessions delivered by the distinguished researchers, scientists and honorary lecturers working in the field of Cardiac vascular disease and pulmonary disorder. Chest 2016 will encourage the participation of the eminent Professors, Chest Physicians, Cardiac surgeons, Pulmonologist, Respiratory Therapist, Lung Association presidents, Researchers and Scholars, Students in all area of Cardiac and Pulmonary disorders and will provide an international forum for the dissemination of original research results, new ideas and practical development experiences concentrating on the scientific development.

Track 1: Neuroscience and Neurology

Cardiology is the division of medicine concerned with the illness of heart and the blood vessels, which also involves diagnosis and treatment of the diseases. Heart diseases are said to be cardiovascular Disease which is a major cause of disability and premature death throughout the world. Acute coronary events (heart attacks) and cerebrovascular events (strokes) occur suddenly, and are often fatal before medical care can be given. Symptoms include shortness of breath, chest pain, and extreme fatigue. Cardiology conferences promote awareness against risk factor modification about the heart diseases. It reduces clinical events and premature death in people with cardiovascular disease risk. Cardiovascular disease is treatable with initial treatment primarily focused on diet and lifestyle interventions.

Related conferences: 6th Clinical & Experimental Cardiology Conference November 30-December 02, 2015 San Antonio, USA, Arrhythmias Congress  July 14-15, 2016 Brisbane, Australia, Cardio Vascular Medicine Conference April 4-6, 2016 Philadelphia, USA, Echocardiography Conference July 18-19, 2016 Berlin, Germany, 8th Annual The Heart Beat of Cardiology- Chicago, United States December 10-12, 2015, World Congress of Cardiology & Cardiovascular Health Mexico City, Mexico June 4-7, 2016, Congress of Echocardiography and Cardiology- Istanbul, Turkey November 20-21 2015,4th European Middle East Forum on Cardiovascular Risks- Budapest, Hungary November 27, 2015, Association of Thoracic and Cardiovascular Surgeons of Asia 25th Annual Congress- Cebu , Philippines November 12-15 2015.

Track 2: Neurosurgery

Stroke is the sudden brain attack. It happens when the blood flow to the brain is blocked or rupturing of blood vessels. Ischemic stroke occurs when an artery to the brain is blocked.  The brain depends on its arteries to bring fresh blood from the heart and lungs. The blood carries oxygen and nutrients to the brain, and takes away carbon dioxide and cellular waste. If an artery is blocked, the brain cells cannot make enough energy and will eventually stop working. If the artery remains blocked for more than a minute, the apoptosis of brain cells will occur and also structural integrity of brain tissue and blood vessel will be lost. The most common problem is narrowing of the arteries in the neck or head. This is most often caused by atherosclerosis, or gradual cholesterol deposition. It is mostly observed in women and children.

Related Conferences:  Annual Conference on Atherosclerosis July 11-12, 2016 Philadelphia, USA; 14th Clinical & Experimental Cardiology  Conference, November 14-16, 2016 Orlando, USA; 8th Cardiologists Annual Meeting, July 18-20 2016, Germany; 13th European Cardiology Congress, October 17-19, 2016 Rome, Italy; 15th World Cardiothoracic Meeting, December 5-6 2016, Philadelphia, USA; 9th Annual Meeting on Arrhythmia and Cardiac Surgery, July 14-15 2016, Australia ;  Hypertension and Health Care, August 11-12, 2016 Toronto, Canada; 4th International Conference on Prehypertension, Hypertension & Cardio Metabolic Syndrome, March 03-06 2016, Italy; The Pacific Northwest Cardiovascular Summit, October 03-04 2015, Oregon; 3rd Annual International Conference on Cardiology & Cardiovascular Medicine Research, February 22-23 2016, Singapore; 3rd International 4 Corners of Cardiology Meeting, February 05-06 2016, Australia.

Track 3: Neuroimmunology and Neuroinflammation

Cardiac arrhythmia means irregular heart beat or heart rhythm where muscles of heart contract in a coordinated fashion to insure that blood is been efficiently pumped into the arteries and the extra heart beat are due to premature atrial contraction and premature ventricular contraction. The electrical impulses are responsible for arrhythmia condition. The Wolff–Parkinson–White syndrome (WPW) is one of the disorders of electrical system of the heart which are commonly referred to as pre-excitation syndromes which is caused by the presence of an abnormal accessory electrical conduction pathways between the atria and ventricles. Treatments may include physical maneuvers, medications, electrical conversion, electro-or cryo-cautery. Arrhythmia can be managed from various ways such as SCA risk assessments, non-invasive techniques, clinical electrophysiology are some clinical techniques and epidemiology of cardiac arrhythmia. 

Related Conferences:  Annual Conference on Atherosclerosis July 11-12, 2016 Philadelphia, USA; 14th Clinical & Experimental Cardiology  Conference, November 14-16, 2016 Orlando, USA; 8th Cardiologists Annual Meeting, July 18-20 2016, Germany; 13th European Cardiology Congress, October 17-19, 2016 Rome, Italy; 15th World Cardiothoracic Meeting, December 5-6 2016, Philadelphia, USA; 9th Annual Meeting on Arrhythmia and Cardiac Surgery, July 14-15 2016, Australia ;  Hypertension and Health Care, August 11-12, 2016 Toronto, Canada; 4th International Conference on Prehypertension, Hypertension & Cardio Metabolic Syndrome, March 03-06 2016, Italy; The Pacific Northwest Cardiovascular Summit, October 03-04 2015, Oregon; 3rd Annual International Conference on Cardiology & Cardiovascular Medicine Research, February 22-23 2016, Singapore; 3rd International 4 Corners of Cardiology Meeting, February 05-06 2016, Australia.

Track 4: Neurological Disorders

Peripheral artery disease (PAD) is a narrowing of the peripheral arteries in legs, stomach, arms, and head by forming plaque inside the arteries. Mostly the arteries of legs get affected. The blocked blood flow to the legs can cause pain and numbness. It can also raise risk of getting an infection resulting in tissue death (gangrene).  PAD increases your risk of coronary heart disease, heart attack, stroke, and transient ischemic attack. PAD can be treated by lifestyle changes, medicines and revascularization.

Related conferences: 6th Clinical & Experimental Cardiology Conference November 30-December 02, 2015 San Antonio, USA, Arrhythmias Congress  July 14-15, 2016 Brisbane, Australia, Cardio Vascular Medicine Conference April 4-6, 2016 Philadelphia, USA, Echocardiography Conference July 18-19, 2016 Berlin, Germany, 8th Annual The Heart Beat of Cardiology- Chicago, United States December 10-12, 2015, World Congress of Cardiology & Cardiovascular Health Mexico City, Mexico June 4-7, 2016, Congress of Echocardiography and Cardiology- Istanbul, Turkey November 20-21 2015,4th European Middle East Forum on Cardiovascular Risks- Budapest, Hungary November 27, 2015, Association of Thoracic and Cardiovascular Surgeons of Asia 25th Annual Congress- Cebu , Philippines November 12-15 2015.

Track 5: Pediatric Neurology

Congenital heart defects are problems with the heart's structure that are present at birth. Congenital heart defects change the normal flow of blood through the heart. This defect develops in the womb, before the baby is born. During pregnancy the mother having some infections such as rubella or poorly controlled type 1 or type 2 diabetes can cause CHD. Some genetic disorders such as Down syndrome or any chromosome defects leads to CHD. Congenital heart disease affects 8 out of every 1,000 newborns. Each year, more than 35,000 babies in the United States are born with congenital heart defects

Related conferences: 6th Clinical & Experimental Cardiology Conference November 30-December 02, 2015 San Antonio, USA, Arrhythmias Congress  July 14-15, 2016 Brisbane, Australia, Cardio Vascular Medicine Conference April 4-6, 2016 Philadelphia, USA, Echocardiography Conference July 18-19, 2016 Berlin, Germany, 8th Annual The Heart Beat of Cardiology- Chicago, United States December 10-12, 2015, World Congress of Cardiology & Cardiovascular Health Mexico City, Mexico June 4-7, 2016, Congress of Echocardiography and Cardiology- Istanbul, Turkey November 20-21 2015,4th European Middle East Forum on Cardiovascular Risks- Budapest, Hungary November 27, 2015, Association of Thoracic and Cardiovascular Surgeons of Asia 25th Annual Congress- Cebu , Philippines November 12-15 2015.

Track 6: Neurodegenerative Diseases

Cardiac surgery is the field of medicine involved in surgical treatment of diseases affecting organs inside the thorax generally treatment of conditions of the heart and lungs by the cardiac surgeons. Coronary artery bypass grafting (CABG) is done to restore normal blood flow to heart muscle. Cardiac cognitive impairment, Cardiac valve disease, Atrial sepal defect repair, Ventricular sepal defect repair are done for cardiac surgery. Pediatric heart surgeons treat complex congenital heart defects in newborns, children, and adolescents. During open heart surgery the heart-lung bypass machine takes over the function of the heart and lungs to provide oxygenated blood to the body. Post-surgical procedure helps the patients to heal the surgical wound and also from infections.

Related Conferences:  Annual Conference on Atherosclerosis July 11-12, 2016 Philadelphia, USA; 14th Clinical & Experimental Cardiology  Conference, November 14-16, 2016 Orlando, USA; 8th Cardiologists Annual Meeting, July 18-20 2016, Germany; 13th European Cardiology Congress, October 17-19, 2016 Rome, Italy; 15th World Cardiothoracic Meeting, December 5-6 2016, Philadelphia, USA; 9th Annual Meeting on Arrhythmia and Cardiac Surgery, July 14-15 2016, Australia ; Hypertension and Health Care, August 11-12, 2016 Toronto, Canada; 4th International Conference on Prehypertension, Hypertension & Cardio Metabolic Syndrome, March 03-06 2016, Italy; American Cardiology Congress 2016; The Pacific Northwest Cardiovascular Summit, October 03-04 2015, Oregon; European Cardiology Congress 2016; 3rd Annual International Conference on Cardiology & Cardiovascular Medicine Research, February 22-23 2016, Singapore; 3rd International 4 Corners of Cardiology Meeting, February 05-06 2016, Australia.

Track 7: Clinical Neuroimmunology

Pulmonary disease is a term that encompasses pathological conditions affecting the organs and tissues of the lungs and the respiratory tract. It includes the upper respiratory tract, trachea, bronchi, bronchioles, alveoli, pleura and pleural cavity. The lung disease may cause inflammation, restrictive or infections to the respective tissues. Major cause of pulmonary disease is due to smoking, occupational exposures and also the genetic makeup of an individual. Pulmonary diseases may also impact newborns, such as pulmonary hyperplasia and Infant respiratory distress syndrome.

Related Conferences: 4th International Conference and Exhibition on Lung and Respiratory Care August 01-03, 2016 Manchester, UK, 5th International Conference on Respiratory and Pulmonologist November 17-18, 2016 Dubai, UAE, 2nd International Conference on Respiratory and Pulmonary Medicine May 09-10, 2016 Chicago, USA, 5th International Conference on Radiology and Imaging September 19-20, 2016 Las Vegas, USA, International Conference on Lung Health- Asthma and COPD, January, 15-17, 2016, Monte-Carlo, Monaco, International Conference on Respiratory Health and Smoking, May 24-26, 2016 London, UK . European Respiratory Society, September 26-30, 2015 Amsterdam, Netherlands. International Conference on Tuberculosis and Respiratory Medicine, December 18-20, 2015 Guilin, China.

Track 8: Autoimmune Disorders and Multiple Sclerosis

Chronic obstructive pulmonary disease (COPD) is a progressive lung disease that makes it hard to breathe. It develops slowly. Symptoms often worsen over time and can limit your ability to do routine activities. Severe COPD may prevent you from doing even basic activities like walking, cooking etc. Alpha1-antitrypsin deficiency (AATD) is a relatively common genetic condition for Chronic obstructive pulmonary disease.  People with AATD are predisposed to obstructive pulmonary disease and liver disease.  Adult stem cell therapy is a new alternative treatment to help manage the complications of COPD. This stem cell heal the plagued cell with disease

Related Conferences: 4th International Conference and Exhibition on Lung and Respiratory Care August 01-03, 2016 Manchester, UK, 5th International Conference on Respiratory and Pulmonologist November 17-18, 2016 Dubai, UAE, 2nd International Conference on Respiratory and Pulmonary Medicine May 09-10, 2016 Chicago, USA, 5th International Conference on Radiology and Imaging September 19-20, 2016 Las Vegas, USA, International Conference on Lung Health- Asthma and COPD, January, 15-17, 2016, Monte-Carlo, Monaco, International Conference on Respiratory Health and Smoking, May 24-26, 2016 London, UK . European Respiratory Society, September 26-30, 2015 Amsterdam, Netherlands. International Conference on Tuberculosis and Respiratory Medicine, December 18-20, 2015 Guilin, China.

Track 9: Neuroendocrinology

Lung cancer is results of unconditional cell growth in tissues of the lungs by the process of metastasis. Large numbers of people are suffering from lung carcinoma due to long time smoking and also second-hand smoke. The abnormal activation of genes in normal cell leads to carcinoma.  Molecular oncology involve in finding out genes that are responsible for the development of cancer. Cancer cells differ from normal cells in size, structure, function, and growth rate. In cancer cells growth rate is faster. Common treatments include palliative care, surgery, chemotherapy, and radiation therapy. Bevacizumab is an anti- angiogenic monoclonal antibody in trials for advanced non- small cell lung cancer treatment.

Related Conferences: 4th International Conference and Exhibition on Lung and Respiratory Care August 01-03, 2016 Manchester, UK, 5th International Conference on Respiratory and Pulmonologist November 17-18, 2016 Dubai, UAE, 2nd International Conference on Respiratory and Pulmonary Medicine May 09-10, 2016 Chicago, USA, 5th International Conference on Radiology and Imaging September 19-20, 2016 Las Vegas, USA, International Conference on Lung Health- Asthma and COPD, January, 15-17, 2016, Monte-Carlo, Monaco, International Conference on Respiratory Health and Smoking, May 24-26, 2016 London, UK . European Respiratory Society, September 26-30, 2015 Amsterdam, Netherlands. International Conference on Tuberculosis and Respiratory Medicine, December 18-20, 2015 Guilin, China.

Track 10: Neurotransmitters and Neuroimmune Interactions

Pulmonary hypertension (PH) is the increase of blood pressure in the pulmonary artery, vein, or capillaries due to the narrowing of arteries and capillaries to and within the lungs, which leads to shortness of breath, dizziness, fainting, leg swelling and other symptoms. Symptoms of pulmonary hypertension do not usually occur until the condition has progressed. The first symptom of pulmonary hypertension is usually shortness of breath with everyday activities, such as climbing stairs. Fatigue, dizziness, and fainting spells also can be symptoms. The molecular mechanism of pulmonary arterial hypertension (PAH) is not known clearly. The endothelial dysfunction decreases the synthesis of endothelium-derived vasodilators such as nitric oxide and prostacyclin. Diagnosis of the severe heart condition includes mainly Echocardiography or as per the signs and symptoms of the particular disease condition. Treatment for pulmonary hypertension will not cure the condition but improve the quality of life.     

Related Conferences: 4th International Conference and Exhibition on Lung and Respiratory Care August 01-03, 2016 Manchester, UK, 5th International Conference on Respiratory and Pulmonologist November 17-18, 2016 Dubai, UAE, 2nd International Conference on Respiratory and Pulmonary Medicine May 09-10, 2016 Chicago, USA, 5th International Conference on Radiology and Imaging September 19-20, 2016 Las Vegas, USA, International Conference on Lung Health- Asthma and COPD, January, 15-17, 2016, Monte-Carlo, Monaco, International Conference on Respiratory Health and Smoking, May 24-26, 2016 London, UK . European Respiratory Society, September 26-30, 2015 Amsterdam, Netherlands. International Conference on Tuberculosis and Respiratory Medicine, December 18-20, 2015 Guilin, China.

Track 11: Neuropsychiatric disorders

Diagnosis is the act or process of identifying the nature and cause of a disease or injury through the systematic analysis of patient signs and symptoms. The physicians will do the physical examination of the patients followed by laboratory test such as Chest x-ray, pulmonary function tests, arterial blood gases, lung scan, Electrocardiogram (ECG), spirometry and Bronchoscopy. Angiography is an x-ray based technique used to image the veins, arteries, blood vessel. It is a part of projection radiography. The angiography devices market is expected to reach $27.7 billion by the year 2019

Related Conferences: 4th International Conference and Exhibition on Lung and Respiratory Care August 01-03, 2016 Manchester, UK, 5th International Conference on Respiratory and Pulmonologist November 17-18, 2016 Dubai, UAE, 2nd International Conference on Respiratory and Pulmonary Medicine May 09-10, 2016 Chicago, USA, 5th International Conference on Radiology and Imaging September 19-20, 2016 Las Vegas, USA, International Conference on Lung Health- Asthma and COPD, January, 15-17, 2016, Monte-Carlo, Monaco, International Conference on Respiratory Health and Smoking, May 24-26, 2016 London, UK . European Respiratory Society, September 26-30, 2015 Amsterdam, Netherlands. International Conference on Tuberculosis and Respiratory Medicine, December 18-20, 2015 Guilin, China.

Track 12: Neuroimmunological Disorders

Chest Imaging interprets cross sectional imaging studies of the heart and pulmonary system using Computed Tomography (CT or "CAT" scans) and Magnetic Resonance Imaging (MRI) with a volume of more than 2,500 studies each year. CT and MRI are non-invasive imaging modalities, meaning that no catheterization is required. MUSC operates the most up-to-date, cutting edge imaging equipment to ensure optimal diagnostic quality in patient care while also minimizing patient exposure to ionizing radiation. The chest radiograph imaging has some limitations in their use.

Related conferences: 6th Clinical & Experimental Cardiology Conference November 30-December 02, 2015 San Antonio, USA, Arrhythmias Congress  July 14-15, 2016 Brisbane, Australia, Cardio Vascular Medicine Conference April 4-6, 2016 Philadelphia, USA, Echocardiography Conference July 18-19, 2016 Berlin, Germany, 8th Annual The Heart Beat of Cardiology- Chicago, United States December 10-12, 2015, World Congress of Cardiology & Cardiovascular Health Mexico City, Mexico June 4-7, 2016, Congress of Echocardiography and Cardiology- Istanbul, Turkey November 20-21 2015,4th European Middle East Forum on Cardiovascular Risks- Budapest, Hungary November 27, 2015, Association of Thoracic and Cardiovascular Surgeons of Asia 25th Annual Congress- Cebu , Philippines November 12-15 2015.

Track 13: Novel Therapeutics

Echocardiography is a painless test that uses sound waves to create moving pictures of your heart. The pictures show the size and shape of your heart. They also show how well your heart's chambers and valves are working. It pin point areas of heart muscle that aren't contracting well because of poor blood flow or injury from a previous heart attack. It also detects possible blood clots inside the heart, fluid buildup in the pericardium and problems with the aorta. The American Society of Echocardiography (ASE) is a professional organization made up of physicians, sonographers, nurses, and scientists involved in the field of echocardiography. Echocardiography is performed by cardiac sonographers, cardiac physiologists (UK) or trained doctors in echocardiography. Echocardiography was invented by Milton R. Hejtmancik, MD, from which he was awarded the AMA Billings Gold Medal in 1972.

Related conferences: 6th Clinical & Experimental Cardiology Conference November 30-December 02, 2015 San Antonio, USA, Arrhythmias Congress  July 14-15, 2016 Brisbane, Australia, Cardio Vascular Medicine Conference April 4-6, 2016 Philadelphia, USA, Echocardiography Conference July 18-19, 2016 Berlin, Germany, 8th Annual The Heart Beat of Cardiology- Chicago, United States December 10-12, 2015, World Congress of Cardiology & Cardiovascular Health Mexico City, Mexico June 4-7, 2016, Congress of Echocardiography and Cardiology- Istanbul, Turkey November 20-21 2015,4th European Middle East Forum on Cardiovascular Risks- Budapest, Hungary November 27, 2015, Association of Thoracic and Cardiovascular Surgeons of Asia 25th Annual Congress- Cebu , Philippines November 12-15 2015.

Track 14: Diagnosis and Therapy

Cardiovascular pharmacology deals with the medication of cardiac diseases. The Cardiac Drugs are used to treat conditions of the heart or the circulatory or vascular system. Many classes of cardiovascular agents are available to treat the various cardiovascular conditions. In this sub topic we have Sodium, potassium, calcium channel blockers, ACE-inhibitors and Cardiac biomarkers. There are 6 associations and societies and the main association for Cardiac Therapeutic Agents in USA. 50 universities are working on Cardiac Therapeutic Agents. Three new drugs were introduced in 2015. There are many types of cardiovascular drugs in the market that include Cardiac glycosides, anti-coagulants, anti-arrhythmic agents, anti-anginal agents and anti-hypertensive agents.

Related Conferences:  Annual Conference on Atherosclerosis July 11-12, 2016 Philadelphia, USA; 14th Clinical & Experimental Cardiology  Conference, November 14-16, 2016 Orlando, USA; 8th Cardiologists Annual Meeting, July 18-20 2016, Germany; 13th European Cardiology Congress, October 17-19, 2016 Rome, Italy; 15th World Cardiothoracic Meeting, December 5-6 2016, Philadelphia, USA; 9th Annual Meeting on Arrhythmia and Cardiac Surgery, July 14-15 2016, Australia ; Hypertension and Health Care, August 11-12, 2016 Toronto, Canada; 4th International Conference on Prehypertension, Hypertension & Cardio Metabolic Syndrome, March 03-06 2016, Italy; American Cardiology Congress 2016; The Pacific Northwest Cardiovascular Summit, October 03-04 2015, Oregon; European Cardiology Congress 2016; 3rd Annual International Conference on Cardiology & Cardiovascular Medicine Research, February 22-23 2016, Singapore; 3rd International 4 Corners of Cardiology Meeting, February 05-06 2016, Australia.

Track 15: Neuropharmacology

Pulmonary therapy includes the program of exercise and treatment to help patients maintain and lung function. The treatments to help lung diseases are postural drainage, suctioning, and breathing exercises. It is defined by the American Thoracic Society and the European Respiratory Society. Pulmonary therapists are specialists and educators in pulmonology. They are often in charge of initiating and managing life support for people in intensive care units and emergency departments. The NICE clinical guideline on chronic obstructive pulmonary disease states that “pulmonary rehabilitation should be offered to every patient who considers themselves functionally disabled by COPD. Medications are Anti-inflammatory agents (inhaled steroids), Bronchodilators, Long-acting bronchodilators, Beta-2 agonists, Anticholinergic agents, Oral steroids, Antibiotics, Mucolytic agents, Oxygen therapy, or Preventative therapy.

Related Conferences: 4th International Conference and Exhibition on Lung and Respiratory Care August 01-03, 2016 Manchester, UK, 5th International Conference on Respiratory and Pulmonologist November 17-18, 2016 Dubai, UAE, 2nd International Conference on Respiratory and Pulmonary Medicine May 09-10, 2016 Chicago, USA, 5th International Conference on Radiology and Imaging September 19-20, 2016 Las Vegas, USA, International Conference on Lung Health- Asthma and COPD, January, 15-17, 2016, Monte-Carlo, Monaco, International Conference on Respiratory Health and Smoking, May 24-26, 2016 London, UK . European Respiratory Society, September 26-30, 2015 Amsterdam, Netherlands. International Conference on Tuberculosis and Respiratory Medicine, December 18-20, 2015 Guilin, China.

Track 16: Heart and lung transplant

A heart transplant or a cardiac transplant is a surgical transplant procedure performed on patients with end-stage heart failure or severe coronary artery disease. Pediatric heart transplantation is important treatment choice in the end stage of heart disease in children. In heart transplantation some post-operative complications are there, those are infections, organ rejection as well as side effects due to immunosuppressive medications. There are selective criteria for potential lung donors due to the needs of the potential recipients, after lung transplantation several pulmonary infection occur especially viral infection by cytomegalovirus and rejection of organ. Cardiothoracic surgery is the field of medicine involved in surgical treatment of organs inside the thorax (the chest). Better supervision of medical complications leads to better long term outcomes.

Related Conferences: International Conference on Internal Medicine November 03-05, 2016 Baltimore, Maryland, USA, 5th World Congress on Cancer Therapy September 28-30, 2015 Atlanta, Georgia, USA, 4th International Conference on Lung and Respiratory Care August 01-02 2016 Manchester UK, 5th International Conference on Respiratory and Pulmonologist November 17-18, 2016 Dubai, UAE, 2nd World Congress on Infectious Diseases August 25-27, 2016 Philadelphia, USA,  Chronic Obstructive Pulmonary Disease, 05 - 06 June 2016 North Carolina, USA, 28th International Conference on Pulmonary and Critical Care Medicine, November 13-14, 2015 Michigan, USA, 38th International Conference on Pulmonary and Allergy, February 3-6, Colorado, USA, International Conference on Pulmonology: Chronic Respiratory Failure, October 6-7, Dhabi, UAE, 46th  International Conference on Lung Health , December 2-6, Cape Town, South Africa, Canadian Lung Association, European Respiratory Society, Japanese Respiratory Society, National Lung Health Education Program, Asian Pacific Society of Respirology.

Track 17: Implantable cardiac devices

The cardiac devices which are implant inside the body will monitor and control the heart rhythms. This devices are programmed to detect abnormal heart rhythms and deliver therapy via programmable anti-tachycardia pacing in addition to low-energy and high-energy shocks. Risk of ICD is that sometimes it leads to infection in the surgical site and failure to deliver therapy when it is needed. The global market for cardiac equipment grew from $49.4 billion in 2013 to $52 billion in 2014.

Related conferences: 6th Clinical & Experimental Cardiology Conference November 30-December 02, 2015 San Antonio, USA, Arrhythmias Congress  July 14-15, 2016 Brisbane, Australia, Cardio Vascular Medicine Conference April 4-6, 2016 Philadelphia, USA, Echocardiography Conference July 18-19, 2016 Berlin, Germany, 8th Annual The Heart Beat of Cardiology- Chicago, United States December 10-12, 2015, World Congress of Cardiology & Cardiovascular Health Mexico City, Mexico June 4-7, 2016, Congress of Echocardiography and Cardiology- Istanbul, Turkey November 20-21 2015,4th European Middle East Forum on Cardiovascular Risks- Budapest, Hungary November 27, 2015, Association of Thoracic and Cardiovascular Surgeons of Asia 25th Annual Congress- Cebu , Philippines November 12-15 2015.

Track 18: Case reports on cardiac and pulmonary diseases

CVDs are the number 1 cause of death globally. More people die annually from CVDs than from any other cause. In 2012, 17.5 million people died due cardiac vascular disease. More than 3 million died due to COPD’s. 235 million people suffer from asthma, which is common among the children. Cardiac vascular disease and pulmonary disease are very invasive among developing countries than the developed countries. The aim of the WHO Chronic Respiratory Diseases Programme is to support Member States in their efforts to reduce the toll of morbidity, disability and premature mortality related to chronic respiratory diseases, and specifically, asthma and chronic obstructive pulmonary disease.

Related conferences: 6th Clinical & Experimental Cardiology Conference November 30-December 02, 2015 San Antonio, USA, Arrhythmias Congress  July 14-15, 2016 Brisbane, Australia, Cardio Vascular Medicine Conference April 4-6, 2016 Philadelphia, USA, Echocardiography Conference July 18-19, 2016 Berlin, Germany, 8th Annual The Heart Beat of Cardiology- Chicago, United States December 10-12, 2015, World Congress of Cardiology & Cardiovascular Health Mexico City, Mexico June 4-7, 2016, Congress of Echocardiography and Cardiology- Istanbul, Turkey November 20-21 2015,4th European Middle East Forum on Cardiovascular Risks- Budapest, Hungary November 27, 2015, Association of Thoracic and Cardiovascular Surgeons of Asia 25th Annual Congress- Cebu , Philippines November 12-15 2015.

Market Analysis Report

Geographically, the market for Cardiology diseases, Pulmonology and Respiratory disorders and biomarkers can be segmented into four regions namely North America, Europe, Asia-Pacific and Rest of the World. Currently North America and Europe account for the largest share of the market. It has been estimated that approximately 8.7 million people are suffering from Pulmonary or Respiratory system disorders such as COPD, Lung Cancer, Pneumonia, Chronic Bronchitis and sleep disorders and others. The global market for asthma and chronic obstructive pulmonary disease (COPD) prescription drugs was valued at $34.9 billion in 2011. This figure is projected to reach $38 billion in 2012 and $47.1 billion in 2017, increasing at a five-year compound annual growth rate (CAGR) of 4.4%. According to the Centers for Disease control and Management in the U.S. about 1 in 4 adults suffer from respiratory disorders every year, with almost 6.8% of the population suffer from serious illness. The idiopathic pulmonary fibrosis (IPF) therapy market across the US and EU will surpass $1 billion by 2017, and pharma companies could stand to benefit handsomely if they can add to the limited knowledge of the disease, states new analysis by research and consulting firm Global Data.

Cardiovascular disease is the leading global cause of death, accounting for 17.3 million deaths per year estimated that 31 % of death all over the world. It is expected to grow to more than 23.6 million by 2030. In this 80% of the deaths taking place in low- and middle-income countries. Nearly 787,000 people in the U.S. died from heart disease, stroke and other cardiovascular diseases in 2011.Cardiovascular diseases claim more lives than all forms of cancer combined.

Direct and indirect costs of cardiovascular diseases and stroke total more than $320.1 billion. That includes health expenditures and lost productivity. Nearly 80% of cardiovascular disease deaths are due to heart attack and stroke. Trends in CVD mortality in the last few years show a minor reduction due to preventive efforts especially against smoking, an operational action plan to reduce the burden of tobacco use

The new research states that over 70,000 people in the US and EU are thought to suffer from IPF, representing a commercially attractive patient population size with a financially appealing orphan drug status Global Data expects IPF therapy sales across the US, France, Germany, Italy, Spain, and the UK to rise from $49m in 2012 to over $1.1 billion by 2017, at a Compound Annual Growth Rate (CAGR) of 86.6%. The EU has so far dominated the IPF market, but the US is set to reclaim market share in the future.

The IPF therapeutics market in the US is predicted to grow from a value of $6.5m in 2012 to $696m in 2017, at a Compound Annual Growth Rate (CAGR) of 154%. Thus, for the diagnosis of these disorders rapidly new methods are being developed for more patients centered and personalized treatment. In the near future Asia-Pacific region is expected to witness significant growth to meet the massive unmet need for early diagnosis and disease monitoring. . According to study, Market Value for Pulmonology will be more than expected as nearly 14.1% of the world’s population will be affected by respiratory disorders by 2020 thus triggering manufacturers to undertake this market. A major part of research is going on the top Universities on Pulmonology and Respiratory disorders across the globe. Many companies are associated with various diagnostic instruments and other therapeutics. Besides this various societies and research labs are also associated in this research field.

According to the study, the global pulmonary drug delivery systems market is anticipated to grow from a value of US$21.0 billion in 2012 to US$28.7 billion in 2019, at a 4.50% CAGR during that period. The primary factor propelling the pulmonary drug delivery systems market is the rising incidence of asthma, chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis. According to the World Health Organization, in 2012, over 3 million people died of COPD, amounting to 6.0% of all deaths that occurred around the globe that year. By 2030, this disease is estimated to become the third leading cause of death worldwide. WHO also states that an estimated 235 million people presently suffer from asthma and it is the most common non-communicable disease among children. The U.S. Cystic Fibrosis Foundation reveals that an estimated 70,000 people worldwide and 30,000 people in the U.S. are living with cystic fibrosis. Each year, approximately 1,000 new cases of cystic fibrosis are diagnosed.

Why it’s in Dubai, UAE?

Dubai is located on the southeast coast of the Persian Gulf and is one of the seven emirates that make up the country. Dubai has veto power over critical matters of national importance in the country's legislature. Dubai has emerged as a global city and business hub of the Middle East. The hazy weather conditions in Dubai such as sandstorms rage affects the health of the people and cause respiratory disorder such as asthma, emphysema, bronchitis and chronic obstructive lung diseases (COPD). UAE healthcare market is one of the fastest growing markets in the world with the growth rate of ~% from 2010 to 2015. The market is also expected to experience high growth during the forecast period and exhibit a CAGR of ~% from 2016 to 2020.

Ø  RAK Hospital

Ø  Saudi German Hospital

Ø  NMC Healthcare and Heart care

Ø  Canadian Specialist Hospital

Ø  Al Zahra Medical Center

Ø  The Iranian Hospital Dubai

Ø  Emirates Hospital

Ø  Burjeel hospital

Ø  American Hospital Dubai

Top Associations around the Globe

Ø  Association of Pulmonary , Critical Care Medical Program

Ø  Pulmonary Hypertension Association

Ø  American Association for Thoracic Surgery

Ø  Pulmonary Fibrosis Foundation

Ø  Patrolmen’s Benefit Association

Ø  Around 80 associations of Pulmonology are there in USA

Ø  American Association for Respiratory Care

Ø  Pulmonary Hypertension Association

Ø  World Association of Bronchology and Interventional Pulmonology

Ø  Texas Association of Cardiovascular and Pulmonary Rehabilitation

Ø  Pulmonary Pathology Society

Ø  COPD Foundation

Ø  Pulmonary and Medical Associates of North Virginia

Ø  Respiratory Nursing Society

Ø  Malaysian Association for Bronchology and Interventional Pulmonology

Ø  PHA Europe

Ø  Ashrai Associations

Ø  Idiopathic Pulmonary Fibrosis

Ø  Association of Pulmonary Tuberculosis and Diabetics

Ø  Idaho Pulmonary Associations

Ø  El Paso Pulmonary Association

Ø  American College of Chest Physicians

Ø  International Society of Heart and Lung Transplantation

Ø  Spanish Society of Pulmonology and Thoracic Surgery

Ø  Association of Pediatric Cardiology

Top universities 500 globally working in the field of Respiratory Research

Ø  National Jewish Health

Ø  Duke University Medical Centre

Ø  UPMC University of Pittsburg

Ø  Washington University

Ø  Vanderbilt University Medical Centre

Ø  Thomas Jefferson University

Ø  New York Presbyterian University Hospital of Columbia and Cornell

Ø  Cleveland Clinic

Ø  UC San Diego Medical Center

Ø  University of California.

Top Universities working in the field of Cardiology

Ø  Swansea University

Ø  Milwaukee Area Technical College

Ø  The University of Sydney

Ø  Plymouth University

Ø  University College Cork

Ø  National University of Singapore (NUS)

Ø  Middlesex University

Ø  Imperial College London

Ø  University of Leeds

Ø  University of Delaware

Ø  Anglia Ruskin University

Ø  Pennsylvania College of Health Sciences

Ø  Garden City Community College

Ø  Canisius College

Ø  Florida South-Western State College

Ø  El Centro College

Hospitals with cardiovascular program

Ø  Barnes-Jewish Hospital/Washington University (St. Louis)

Ø  Baylor Heart and Vascular Hospital

Ø  Beaumont Hospital

Ø  Boca Raton Community Hospital 

Ø  Brigham and Women's Hospital

Ø  Cleveland Clinic

Ø  Hospital of the University of Pennsylvania

Ø  Johns Hopkins Hospital

Ø  Mayo Clinic

Ø  Massachusetts General Hospital

Ø  New York-Presbyterian University Hospital

Ø  Northwestern Memorial Hospital

Ø  Rochester General Hospital

Ø  Ronald Reagan UCLA Medical Center

Ø  Rush University Medical Center

Ø  Scripps Memorial Hospital

Past Conference Report

Pediatric Cardiology-2015

International Conference and Exhibition on Pediatric cardiology 2015 held during August 25-27, 2015 at Valencia, Spain, Europe, was a dynamic forum for all cardiologists, healthcare professionals, scientists and medical executives from around the world who are actively involved in patient care, research, therapeutics development including basic, translational, and clinical aspects, epidemiology, prevention, diagnosis, Surgery, and drug discovery and development. The conference provided participants a platform to exchange ideas, and to share breakthroughs and promising solutions to the most important issues in the field.

The day featured formal presentations from key researchers as well as time for questions and informal discussion. The theme of the conference was “Challenges in pediatric and congenital cardiac disease”.

Keynote sessions were delivered by great speakers, Christopher Snyder, Rainbow Babies and Children’s Hospital, USA, Bryan Cannon, Mayo Clinic Rochester, USA Sofia Grinenco, Hospital Italiano, Brojendra Agarwala, University of Chicago, Comer Children’s Hospital, USA, Maurice J B van den Hoff, University of Amsterdam, Netherlands. They made excellent presentations and their experiences gained inside/outside the lab were warmly discussed with the audiences at the keynote forum.

The conference was chaired by Jie Tian Flavia Ventriglia, Christopher Snyder, Brojendra Agarwala, Xupei Huang, Bryan Cannon.

Global summit on stroke held during August 03-05, 2015 at Birmingham, UK, was a dynamic forum for all cardiologists, healthcare professionals, scientists and medical executives from around the world who are actively involved in patient care, research, therapeutics development including basic, translational, and clinical aspects, epidemiology, prevention, diagnosis, and drug discovery and development. The conference provided participants a platform to exchange ideas, and to share breakthroughs and promising solutions to the most important issues in the field.

The day featured formal presentations from key researchers as well as time for questions and informal discussion. The theme of the conference was “Developing trends and new advances in stroke treatment & prevention”.

Keynote sessions were delivered by great speakers, Howard Prentice, Florida Atlantic University, USA, Xin Wang, Harvard Medical School, USA, Saema Ansar, Lund University, Sweden, Benjamin Chitambira, East Kent Hospitals University NHS Foundation Trust, UK. They made excellent presentations and their experiences gained inside/outside the lab were warmly discussed with the audiences at the keynote forum.

The conference was chaired by Naomi Josman, Xin Wang, Ihor Huk, Ying Li, Stefan Golaszewski, Sikha Saha, Alexander D. Verin.

International Conference and exhibition on Lung disorder and therapeutics-2015 held during July 13-15, 2015 at Baltimore, Maryland, USA, was a dynamic forum for all pulmonologists, healthcare professionals, scientists and medical executives from around the world who are actively involved in patient care, research, therapeutics development including basic, translational, and clinical aspects, epidemiology, prevention, diagnosis, and drug discovery and development. The conference provided participants a platform to exchange ideas, and to share breakthroughs and promising solutions to the most important issues in the field.

The day featured formal presentations from key researchers as well as time for questions and informal discussion. The theme of the conference was “Optimizing research strategies for breakthrough innovations in Lung disorders treatment”.

Keynote sessions were delivered by great speakers, Alexander D Verin, Georgia Regents University, USA, Ahmed Al-Jumaily, Auckland University of Technology, New Zealand, Janet M Urban, Motivator Tobacco Treatment and Wellness Services, USA, Akiko Mammoto, Boston Children’s Hospital, USA. They made excellent presentations and their experiences gained inside/outside the lab were warmly discussed with the audiences at the keynote forum.

The conference was chaired by Janet M Urban, Amarjit Mishra, Ahmed Al-Jumaily, Du Toit Loots, Samuel C. Dudley, Daqing Ma, Alexander D. Verin.

3rd International Conference on Clinical & Experimental Cardiology (Cardiology -2013) held during April 15-17, 2013 at Chicago/Northbrook, USA, was a dynamic forum for all cardiologists, healthcare professionals, scientists and medical executives from around the world who are actively involved in patient care, research, therapeutics development including basic, translational, and clinical aspects, epidemiology, prevention, diagnosis, and drug discovery and development. The conference provided participants a platform to exchange ideas, and to share breakthroughs and promising solutions to the most important issues in the field.

The day featured formal presentations from key researchers as well as time for questions and informal discussion. The theme of the conference was “Emerging interventions in clinical cardiology and cardiac surgery”.

Keynote sessions were delivered by great speakers, Louis E Samuels, Lankenau Medical Center, USA, Vincent DOR, Centre Cardiothoracique de Monaco, Monaco Cedex, Richard J Frink, Heart Research Foundation of Sacramento, USA, Ming K Heng, University of California, USA. They made excellent presentations and their experiences gained inside/outside the lab were warmly discussed with the audiences at the keynote forum.

The conference was chaired by Xiaoping Ren, James D Fett, Ming k heng, Emad Aziz, Samuel C. Dudley, Anthony Ashton, Alexander D. Verin, Anastasia Susie Mihailidou, JanGlatz, Mentzer, Dr. Ramin Artang, Louis Samuels, and Geetha Bhat.

During the conference, a workshop was introduced by Jozsef Pal Vas and Noemi Csaszar, Hungarian Association of Hypnosis, Hungary. The title for the workshop was “Tandem hypnotherapy (THT) as a new method functioned at sensori-motor level”.

Along with the participants of Cardiology Conference, we would like to express our gratitude to Mr. Frank King, The Cardiac Comedian, for his special appearance at the conference.

The warm support and suggestions from all the participants, inspires us in organizing “4th International Conference on Clinical & Experimental Cardiology” which will be held during April 2014 in San Antonio, USA.